Oncology

Israeli startup Protai is set to reveal promising preclinical data for its cancer drug, PRT-001, powered by its unique proteomics-aware AI platform.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

AB Science's Masivet gets key FDA designation, paving the way for a new targeted cancer therapy for dogs and a major strategic win for the company.

A new pilot program uses AI to find hidden patterns in past cancer trial data, aiming to get the right drugs to the right patients, faster.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

A groundbreaking dual-payload ADC from Kanghong Pharmaceutical has entered clinical trials, a major milestone in oncology accelerated by partner BioDlink.

The Middle East healthcare giant posts record profits and a $163M dividend, fueled by aggressive international acquisitions and a major bet on AI technology.

A 15-year pharma alliance expands to Austria, bringing advanced relief to cancer patients suffering from chemotherapy's debilitating side effects.

Median Technologies' eyonis® LCS gains landmark FDA clearance, promising to revolutionize early detection of the deadliest cancer with its AI-powered diagnostics.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

Kelun-Biotech's sac-TMT gains its fourth approval in China, doubling survival time for patients with advanced HR+/HER2- breast cancer.

A new cancer drug using DNA fragments to deliver chemotherapy more safely has been cleared for US trials, offering hope for less toxic treatments.

Manipal's new comprehensive cancer centre in South Bengaluru integrates robotic surgery, precision radiation, and holistic support to combat rising cancer rates.

Akeso's innovative dual-action antibody secures its fifth breakthrough nod, offering a lifeline for patients with advanced biliary tract cancer.

Stunning real-world data shows Iovance's Amtagvi is more effective in earlier melanoma treatment, potentially changing clinical practice and offering new hope.

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

For the third consecutive year, Virginia Cancer Specialists has been named the top practice in Virginia. We explore how they achieved this sustained success.

Despite product withdrawals, a lack of regulation and the long latency of asbestos-related diseases mean the danger from talc exposure is far from over.